STREPTOZOTOCIN-INDUCED TYPE 1 DIABETES MELLITUS: FORMATION MECHANISMS AND PRACTICAL ASPECTS OF EXPERIMENTAL MODELING (literature review)*

Authors

  • Poltorak V. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • Gladkykh O. I. SI «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • Mishchenko T. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine; 2 V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
  • Krasova N. S. SI «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • Leshchenko Zh. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • Tyzhnenko T. V. SI «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine; 2 V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
  • Plokhotnichenko O. O. SI «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2018.2.08

Keywords:

streptozotocin, type 1 diabetes mellitus, animal model

Abstract

In the review the present-day views about mechanisms of streptozotocin-induced type 1 diabetes mellitus
development and methodical recommendations for its experimental modeling are presented. The mechanisms of
streptozotocin-induced insulin-dependent diabetes mellitus development have been considered according to four
ways of the diabetogen influence on β-cells:
1) DNA alkylating;
2) donating NO/NO expression intensification;
3) oxidative stress development;
4) lowering N-acetyl-β-D-glucosaminidase activity.
Methodical recommendations for streptozotocin-induced type 1 diabetes mellitus experimental modeling
are presented by the criteria:
1) animal species, breed, line;
2) animal gender;
3) animal age;
4) number of streptozotocin administrations;
5) recommended streptozotocin dose;
6) streptozotocin solution preparation;
7) routs of streptozotocin administration;
8) streptozotocin-induced type 1 diabetes mellitus correction.

References

Harwood HJ, Listrani P, Wagner JD J Diab Sci & Tech 2012; 6 (3): 503-514.

Like AA, Rossini AA. Science 1976; 193 (4251): 415-417.

Wu J, Yan LJ. Diabetes Metab Syndr Obes 2015; 8: 181-188.

Herr RR, Eble TE, Bergy ME, et al. Antibiot Annu 1959; 7: 236-240.

Herr RR, Jahnke HK, Argoudelis AD. J Am Chem Soc 1967; 89: 4808-4809.

Lenzen S. Diabetoligia 2008; 51: 216-226.

Rakieten L, Rakieten ML, Nadkarni MV. Cancer Chem Rep 1963; 29: 91-98.

Szkudelski T. Physiol Res 2001; 50: 536-546.

Schein PS, Loftus S. Cancer Res 1968; 28: 1501-1506.

Elsner M, Guldbakke B, Tiedge M, et al. Diabetologia 2000; 43 (12): 1528-1533.

Schnedl WJ, Ferber S, Johnson JH, et al. Diabetes 1994; 43: 1326-1333.

Dufrane D, Van Steenberghe M, Guiot Y, et al. Transplantation 2006; 81 (1): 36-45.

Karunanayake EH, Hearse DJ, Mellows G. Biochem J 1974; 142: 673-683.

Graham ML, Mutch LA, Kittredge JA, et al. Lab Anim 2012; 46: 178-192.

Goud BJ, DwarakanathV, Swamy BK. IJPPR 2015; 3 (1): 253-269.

Bathaie SZ, Sedghgoo F, Jafarnejad A, et al. Spectrochim Acta A Mol Biomol Spectrosc 2008; 71 (3): 803-808.

Bennett RA, Pegg AE. Cancer Res 1981; 41 (7): 2786-2690.

Yamamoto H, Uchigata Y, Okamoto H. Nature 1981; 294(5838):284-286.

Gunnarsson R, Berne C, Hellerström C. Biochem J 1974; 140 (3): 487-494.

Okamoto H, Yamamoto H. Princess Takamatsu Symp 1983; 13: 297-308.

Kröncke KD, Fehsel K, Sommer A, et al. Biol Chem Hoppe Seyler 1995; 376 (3): 179-185.

Kwon NS, Lee SH, Choi CS, et al. FASEB J 1994; 8 (8): 529-533.

Turk J, Corbett JA, Ramanadham S, et al. Biochem Biophys Res Commun 1993; 197 (3): 1458-1464.

Eizirik DL, Pavlovic D. Diabetes 1997; 13: 293-307.

Herold KC, Vezys V, Sun Q, et al. J Immunol 1996; 156 (9): 3521-3527.

Lukić ML, Stošić-Grujičić S, Shahin A. Dev Immunol 1998; 6 (1-2): 119-128.

Paik SG, Fleischer N, Shin SI. Proc Natl Acad Sci USA 1980; 77 (10): 6129-6133.

Corbett JA, McDaniel ML. J Exp Med 1995; 181 (2): 559-568.

Kaneto H, Fujii J, Seo HG, et al. Diabetes 1995; 44 (7): 733-738.

Martin AP, Alexander-Brett JM, Canasto-Chibuque C, et al. J Immunol 2007; 178: 4623-4631.

Corbett JA, Sweetland MA, Wang JL, et al. PNAS 1993; 90 (5): 1731-1735.

Delaney CA, Eizirik DL. Braz J Med Biol Res 1996; 29 (5): 569-579.

Katakam AK, Chipitsyna G, Gong Q, et al. J Endocrinol 2005; 187: 237-247.

Nukatsuka M, Yoshimura Y, Nishida M, et al. J Endocrinol 1990; 127 (1): 161-165.

Ivanenko TV, Abramov AV, Kolesnik JuM, et al. Patologija 2011; 8 (2):18-20.

Nahdi AM, John A, Raza H. Oxid Med Cell Longev 2017; 2017: e7054272.

Takasu N, Komiya I, Asawa T, et al. Diabetes 1991; 40 (9): 1141-1145.

Raza H, Prabu SK, John A, et al. Int J Mol Sci 2011; 12 (5): 3133-3147.

Konrad RJ, Mikolaenko I, Tolar JF, et al. Biochem J 2001; 356 (Part 1): 31-41.

Toleman C, Paterson AJ, Shin R, et al. Biochem Biophys Res Commun 2006; 340: 526-534.

Kushner BS, Lazar M, Furman M, et al. Diabetes 1969; 18 (8): 542-544.

Deeds MC, Anderson JM, Armstrong AS, et al. Lab Anim 2011; 45: 131-140.

Graham ML, Janecek JL, Kittredge JA, et al. Comp Med 2011; 61 (4): 356-360.

Leiter EH. Curr Top Microbiol Immunol 1985; 122: 78-85.

Masutani M, Suzuki H, Kamada N, et al. Proc Natl Acad Sci 1998; 96 (5): 2301-2304.

Costa VA, Vianna LM. Braz Arch Boil Technol 2008; 51 (1): 43-48.

Reaven GM, Ho H. Metabolism 1988; 40 (4): 335-337.

Mir SH, Baqui A, Darzi B, et al. Pak J Nutr 2008; 7 (2): 359-364.

Pitkin RM, Reynolds A. Diabetes 1970; 19 (2): 85-90.

Shibata S, Kirchhof N, Matsumoto S, et al. Transpl Proc 2002; 34: 1341-1344.

Litwak KN, Cefalu WT, Wagner JD. Lab Anim Sci 1998; 48 (2): 172-178.

Zou C, Wang J, Wang S, et al. Sci China Life Sci 2012; 55 (3): 210-218.

White JA, Bolstridge MC, Downing HJ, et al. S Afr Med J 1974; 48 (7): 273-276.

Heffernan S, Phippard A, Sinclair A, et al. J Med Primatol 1995; 24: 29-34.

Zhu H, Yu L, He Y, et al. J Diabetes Res 2014; 2014: e785948.

Di Giacomo RF, Shah K. Lab Anim Sci 1972; 22 (1): 61-67.

Leiter EH. Proc Natl Acad Sci USA 1982; 79: 630-634.

Le May C, Chu K, Hu M, et al. Proc Natl Acad Sci USA 2006; 103: 9232-9237.

Junod A, Lambert E, Stauffacher W, et al. J Clin Invest 1969; 48: 2129-2139.

Reddy S, Wu D, Elliott RB. Autoimmunity 1995; 20 (2): 83-92.

Head RJ, Longhurst PA, Panek RL, et al. Br J Pharmac 1987; 91: 275-286.

Mir MS, Darzi MM, Baba OK, et al. Iran J Pathol 2015; 10 (3): 206-213.

Gaur LK, Nepom GT, Lernmark A. Autoimmunity 2001; 33 (2): 103-114.

Takimoto G, Jones C, Lands W, et al. Metabolism 1988; 37 (4): 364-370.

Rood PP, Bottino R, Balamurugan AN, et al. Pancreas 2006; 33 (3): 287-292.

Koulmanda M, Qipo A, Chebrolu S, et al. Am J Transpl 2003; 3: 267-272.

Rerup CC. Pharmacol Rev 1970; 22 (4): 485-518.

Axler DA. IRCS Med Sci 1982; 10: 157-158.

Oles PJ. J Pharm Sci 1978; 67: 1300-1302.

Rossini AA, Like AA, Dulin WE, et al. Diabetes 1977; 26 (12): 1120-1124.

de la Garza-Rodea AS, Knaän-Shanzer S, den Hartigh JD, et al. J Am Assoc Lab Anim Sci 2010; 49 (1): 40-44.

Fröde TS, Medeiros YS. J Ethnopharm 2008; 115: 173-183.

Luippold G, Bedenik J, Voigt A, et al. PLoS One 2016; 11 (6): e0156346.

Bottino R, Criscimanna A, Casu A, et al. Diabetes 2009; 58: 442-447.

Grossman EJ. PLoS ONE 2010; 5: e8749.

Jörns A, Klempnauer J, Tiedge M, et al. Pancreas 2001; 23 (2): 186-196.

Downloads

Published

2021-08-18

How to Cite

Poltorak, V. V. ., Gladkykh, O. I. ., Mishchenko, T. V. ., Krasova, N. S. ., Leshchenko, Z. A. ., Tyzhnenko, T. V. ., & Plokhotnichenko, O. O. . (2021). STREPTOZOTOCIN-INDUCED TYPE 1 DIABETES MELLITUS: FORMATION MECHANISMS AND PRACTICAL ASPECTS OF EXPERIMENTAL MODELING (literature review)*. Problems of Endocrine Pathology, 64(2), 51-64. https://doi.org/10.21856/j-PEP.2018.2.08

Most read articles by the same author(s)